Zydus Lifesciences Ltd
NSE:ZYDUSLIFE

Watchlist Manager
Zydus Lifesciences Ltd Logo
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Watchlist
Price: 949.05 INR 0.82% Market Closed
Market Cap: 955B INR
Have any thoughts about
Zydus Lifesciences Ltd?
Write Note

Zydus Lifesciences Ltd
Selling, General & Administrative

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Zydus Lifesciences Ltd
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Selling, General & Administrative
-â‚ą32.9B
CAGR 3-Years
-13%
CAGR 5-Years
-9%
CAGR 10-Years
-12%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Selling, General & Administrative
-â‚ą125B
CAGR 3-Years
-13%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Selling, General & Administrative
-â‚ą45.5B
CAGR 3-Years
-10%
CAGR 5-Years
-9%
CAGR 10-Years
-10%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Selling, General & Administrative
-â‚ą96.6B
CAGR 3-Years
-12%
CAGR 5-Years
-9%
CAGR 10-Years
-12%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Selling, General & Administrative
-â‚ą20.8B
CAGR 3-Years
-12%
CAGR 5-Years
-7%
CAGR 10-Years
-10%
M
Mankind Pharma Ltd
NSE:MANKIND
Selling, General & Administrative
-â‚ą33.1B
CAGR 3-Years
-9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Zydus Lifesciences Ltd
Glance View

Market Cap
955B INR
Industry
Pharmaceuticals

Zydus Lifesciences Ltd. is a prominent player in the pharmaceutical landscape, rooted in its rich history and unwavering commitment to innovation. Founded in 1952, the company has evolved from a small enterprise into a global entity, driven by its ambition to provide high-quality and affordable healthcare solutions. With a diverse portfolio that encompasses both generic and branded pharmaceuticals, biosimilars, and consumer health products, Zydus has positioned itself as a key contributor to addressing pressing health needs worldwide. Its state-of-the-art manufacturing facilities and robust R&D capabilities reflect a deep investment in creating cutting-edge therapies that appeal to a growing patient base globally. For investors, Zydus Lifesciences presents a compelling opportunity fueled by strategic expansion and strong financial performance. The company's recent foray into the biopharmaceutical sector, backed by successful launches of innovative therapies and the development of complex generics, indicates a clear path for sustainable growth. Moreover, Zydus has demonstrated resilience in navigating regulatory challenges and market fluctuations, enabling it to establish a solid presence in established and emerging markets alike. As healthcare dynamics shift towards personalized medicine and advanced biologics, Zydus is poised not only to adapt but to lead in these areas, making it an enticing consideration for investors looking to be part of a forward-thinking healthcare company with a solid foundation.

ZYDUSLIFE Intrinsic Value
644.39 INR
Overvaluation 32%
Intrinsic Value
Price

See Also

What is Zydus Lifesciences Ltd's Selling, General & Administrative?
Selling, General & Administrative
-32.9B INR

Based on the financial report for Jun 30, 2024, Zydus Lifesciences Ltd's Selling, General & Administrative amounts to -32.9B INR.

What is Zydus Lifesciences Ltd's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-12%

Over the last year, the Selling, General & Administrative growth was -17%. The average annual Selling, General & Administrative growth rates for Zydus Lifesciences Ltd have been -13% over the past three years , -9% over the past five years , and -12% over the past ten years .

Back to Top